Entecavir, Lamivudine Compared for Preventing Hep B Reactivation in Diffuse Large B-Cell Lymphoma

This article originally appeared here.
Entecavir, Lamivudine Compared
Entecavir, Lamivudine Compared

(HealthDay News) — Entecavir is more efficacious than lamivudine for preventing hepatitis B virus (HBV) reactivation among patients who are seropositive for the hepatitis B surface antigen with diffuse large B-cell lymphoma receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy treatment. These findings have been published in the Dec. 17 issue of the Journal of the American Medical Association.

He Huang, MD, from Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues compared the efficacy of entecavir and lamivudine in preventing HBV reactivation in patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy treatment. Patients were seropositive for the hepatitis B surface antigen and had normal liver function. They were randomized to daily 0.5mg entecavir (61 patients) or 100mg lamivudine (60 patients) beginning one week before R-CHOP initiation.

The researchers found that the incidence of HBV-related hepatitis was significantly lower in the entecavir group than in the lamivudine group (0 vs. 13.3%; P=0.003). The incidence of HBV reactivation was also significantly lower in the entecavir group (6.6 vs. 30.0%; P=0.001), as was chemotherapy disruption (1.6 vs. 18.3%; P=0.002).

"If replicated, these findings support the use of entecavir in these patients," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....